The current study corroborates these data with a statistically significant prolonged brain PFS in patients with hormone receptor-positive/HER2-positive breast cancer compared to the hormone receptor-negative/HER2-positive subtype. This evidence concerns the gene ERBB2 and breast carcinoma.